Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Immunome Inc’s stock clocked out at $10.04, down -5.28% from its previous closing price of $10.60. In other words, the price has decreased by -$5.28 from its previous closing price. On the day, 1.04 million shares were traded. IMNM stock price reached its highest trading level at $10.485 during the session, while it also had its lowest trading level at $9.37.
Ratios:
To gain a deeper understanding of IMNM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.17 and its Current Ratio is at 6.17. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $30.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.
On April 30, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $24.JP Morgan initiated its Overweight rating on April 30, 2024, with a $24 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 21 ’24 when SIEGALL CLAY B bought 66,057 shares for $9.54 per share. The transaction valued at 630,263 led to the insider holds 485,693 shares of the business.
SIEGALL CLAY B bought 33,943 shares of IMNM for $331,918 on Nov 22 ’24. The President and CEO now owns 519,636 shares after completing the transaction at $9.78 per share. On Nov 21 ’24, another insider, Lechleider Robert, who serves as the Chief Medical Officer of the company, bought 15,805 shares for $9.48 each. As a result, the insider paid 149,800 and bolstered with 15,805 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMNM now has a Market Capitalization of 661618944 and an Enterprise Value of 386535136. For the stock, the TTM Price-to-Sale (P/S) ratio is 61.86 while its Price-to-Book (P/B) ratio in mrq is 2.82. Its current Enterprise Value per Revenue stands at 38.161 whereas that against EBITDA is -3.5.
Stock Price History:
The Beta on a monthly basis for IMNM is 1.91, which has changed by -0.23905241 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, IMNM has reached a high of $30.96, while it has fallen to a 52-week low of $8.97. The 50-Day Moving Average of the stock is -14.63%, while the 200-Day Moving Average is calculated to be -28.12%.
Shares Statistics:
It appears that IMNM traded 789.15K shares on average per day over the past three months and 775970 shares per day over the past ten days. A total of 60.42M shares are outstanding, with a floating share count of 51.30M. Insiders hold about 17.80% of the company’s shares, while institutions hold 81.92% stake in the company. Shares short for IMNM as of 1734048000 were 8800956 with a Short Ratio of 12.51, compared to 1731628800 on 10670039. Therefore, it implies a Short% of Shares Outstanding of 8800956 and a Short% of Float of 14.879999999999999.
